

**DIVI'S LABORATORIES LIMITED**

UN-AUDITED FINANCIAL RESULTS (STANDALONE)  
FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>st</sup> DECEMBER, 2014

PART-I

(Rs.in Lakhs)

	Particulars	STANDALONE					
		Quarter ended			Nine Months ended		Year Ended
		31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	<b>Income from operations</b>	<b>78808</b>	82977	68741	<b>225761</b>	176917	250718
	(a) Net Sales/Income from operations (Net of Excise Duty)						
	(b) Other Operating Income	<b>304</b>	337	186	<b>931</b>	420	679
	<b>Total Income from operations (net)</b>	<b>79112</b>	83314	68927	<b>226692</b>	177337	251397
2	<b>Expenses</b>						
	a. Cost of materials consumed	<b>34672</b>	41097	24473	<b>105441</b>	81011	103189
	b. Purchases of stock-in-trade		0	0		0	0
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(2808)</b>	(6040)	1151	<b>(13626)</b>	(19622)	(11375)
	d. Employee benefits expense	<b>7459</b>	6948	5710	<b>20425</b>	16628	22543
	e. Depreciation and amortization expense	<b>2879</b>	2926	2327	<b>9131</b>	6667	9206
	f. Other Expenses	<b>11080</b>	10629	8814	<b>31546</b>	25417	35154
	<b>Total Expenses</b>	<b>53282</b>	55560	42475	<b>152917</b>	110101	158717
3	<b>Profit from Operations before Other Income, Finance Costs &amp; Exceptional Items (1-2)</b>	<b>25830</b>	27754	26452	<b>73775</b>	67236	92680
4	Other Income	<b>1994</b>	1554	791	<b>4817</b>	9253	8390
5	<b>Profit from ordinary activities before finance costs &amp; exceptional Items (3+4)</b>	<b>27824</b>	29308	27243	<b>78592</b>	76489	101070
6	Finance Costs	<b>48</b>	43	35	<b>127</b>	115	206
7	<b>Profit from ordinary activities after finance costs but before exceptional Items (5-6)</b>	<b>27776</b>	29265	27208	<b>78465</b>	76374	100864
8	Exceptional items	<b>0</b>	0	0	<b>0</b>	0	0
9	<b>Profit from ordinary activities before Tax (7-8)</b>	<b>27776</b>	29265	27208	<b>78465</b>	76374	100864
10	Tax Expense	<b>5718</b>	6301	5306	<b>16650</b>	16508	21692
11	<b>Net Profit from ordinary activities after Tax (9-10)</b>	<b>22058</b>	22964	21902	<b>61815</b>	59866	79172
12	Extra-ordinary items (net of tax expense)	<b>0</b>	0	0	<b>0</b>	0	0
13	<b>Net Profit (+)/Loss(-) for the period (11-12)</b>	<b>22058</b>	22964	21902	<b>61815</b>	59866	79172
14	Share of profit / (loss) of associates	<b>0</b>	0	0	<b>0</b>	0	0
15	Minority Interest	<b>0</b>	0	0	<b>0</b>	0	0

16	<b>Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)</b>	<b>22058</b>	22964	21902	<b>61815</b>	59866	79172
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	<b>2655</b>	2655	2655	<b>2655</b>	2655	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						300787
19.i	<b>Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):</b>						
	a) Basic	<b>16.62</b>	17.30	16.50	46.57	45.10	59.65
	b) Diluted	<b>16.62</b>	17.30	16.50	46.57	45.10	59.65
19.ii	<b>Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):</b>						
	a) Basic	<b>16.62</b>	17.30	16.50	46.57	45.10	59.65
	b) Diluted	<b>16.62</b>	17.30	16.50	46.57	45.10	59.65

PART-II - SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>st</sup> DECEMBER, 2014

<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
1	Public shareholding - No. of shares - Percentage of shareholding	<b>63603674</b> <b>47.92%</b>	63603674 47.92%	63556194 47.88%	<b>63603674</b> <b>47.92%</b>	63556194 47.88%	63603674 47.92%
2	Promoters and promoter group shareholding a) <b>pledged / encumbered</b> b) <b>non-encumbered:</b> - No. of shares - Percentage of shares (as a % of the total shareholding of the promoter group) - Percentage of shares (as a % of the total share capital of the company)	<b>Nil</b> <b>69130616</b> <b>100%</b> <b>52.08%</b>	Nil 69130616 100%	Nil 69178096 100%	<b>Nil</b> <b>69130616</b> <b>100%</b> <b>52.08%</b>	Nil 69178096 100%	Nil 69130616 100%

	<b>Particulars</b>	<b>Quarter ended 31-12-2014</b>
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	13
	Disposed off during the quarter	13
	Remaining unresolved at the end of the quarter	Nil

**NOTES:**

1. The above results for the quarter ended 31<sup>st</sup> December 2014, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 31<sup>st</sup> January, 2015 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.

4. Details of forex gain/loss are given below:

Particulars	Quarter ended			Nine Months ended		Year Ended
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Forex Gain/(Loss)	1116	432	(534)	1683	6842	5042

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. As per the requirements of the Companies Act, 2013 ("the Act"), the company has computed depreciation on the basis of the estimated economic lives or useful lives of fixed assets in the manner prescribed in Schedule II of the Act. Consequently, depreciation for the quarter ended 31<sup>st</sup> December, 2014 is higher by ₹ 60 lakhs and ₹ 765 lakhs for the 9 months ended 31<sup>st</sup> December, 2014. Depreciation of ₹ 1051 lakhs (net of deferred tax) on account of assets whose useful life is already exhausted as on 1<sup>st</sup> April 2014 has been adjusted to Retained Earnings.
6. Figures for the previous year/period have been regrouped or reclassified, wherever necessary.

for Divi's Laboratories Limited

Place: Hyderabad  
Date: 31-01-2015

Dr. Murali K. Divi  
Chairman & Managing Director